Alphamab Oncology

SEHK:9966 Stock Report

Market Cap: HK$3.1b

Alphamab Oncology Future Growth

Future criteria checks 5/6

Alphamab Oncology is forecast to grow earnings and revenue by 50.4% and 35.2% per annum respectively.

Key information

50.4%

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth39.3%
Revenue growth rate35.2%
Future return on equity-11.3%
Analyst coverage

Low

Last updated29 Jan 2025

Recent future growth updates

Recent updates

After Leaping 31% Alphamab Oncology (HKG:9966) Shares Are Not Flying Under The Radar

Nov 14
After Leaping 31% Alphamab Oncology (HKG:9966) Shares Are Not Flying Under The Radar

Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

Sep 30
Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Jun 20
Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

May 06
Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Mar 13
Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Jan 17
Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

May 21
Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Mar 01
Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Oct 04
Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Is Alphamab Oncology (HKG:9966) A Risky Investment?

May 21
Is Alphamab Oncology (HKG:9966) A Risky Investment?

Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Oct 05
Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Earnings and Revenue Growth Forecasts

SEHK:9966 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,684751786N/A1
12/31/2026720201243N/A3
12/31/2025432-134-85N/A3
12/31/2024338N/A-55N/A3
6/30/2024256-216-194-175N/A
3/31/2024237-213-217-189N/A
12/31/2023219-211-239-203N/A
9/30/2023234-214-277-215N/A
6/30/2023250-218-315-228N/A
3/31/2023208-272-372-264N/A
12/31/2022167-326-430-300N/A
9/30/2022183-309-423-275N/A
6/30/2022200-292-416-251N/A
3/31/2022173-352-447-286N/A
12/31/2021146-412-479-321N/A
9/30/202173-502-499-368N/A
6/30/2021N/A-592-519-415N/A
3/31/2021N/A-510-478-381N/A
12/31/2020N/A-428-438-347N/A
9/30/20201-652-422-305N/A
6/30/20202-877-406-263N/A
3/31/2020-1-851-423-261N/A
12/31/20195-833-397-225N/A
9/30/20193-495-347-201N/A
6/30/20191-157-298-177N/A
3/31/20196-176-207-113N/A
12/31/2018-1-150-167-94N/A
12/31/20171-33N/A-65N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 9966 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: 9966 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 9966 is expected to become profitable in the next 3 years.

Revenue vs Market: 9966's revenue (35.2% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).

High Growth Revenue: 9966's revenue (35.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 9966 is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 02:33
End of Day Share Price 2025/01/28 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alphamab Oncology is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wangbin ZhouCitigroup Inc
null nullCLSA
null nullGuoyuan Securities (HK) Ltd